(Q37364849)

19 August 2017

1 reference

title

The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease (English)

1 reference

19 August 2017

1 reference

1 reference

Fabrizio Stocchi

1

0 references

publication date

1 January 2009

1 reference

Parkinsonism and Related Disorders

19 August 2017

published in

1 reference

19 August 2017

volume

15 Suppl 1

1 reference

19 August 2017

page(s)

S9-S15

1 reference

An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Levodopa: why the controversy?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Treatment interventions for Parkinson's disease: an evidence based assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Emerging therapies in the pharmacological treatment of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Success and problems of long-term levodopa therapy in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

1 reference

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

The Long-Duration Action of Levodopa May Be Due to a Postsynaptic Effect

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

The long-duration response to L-dopa in the treatment of early PD.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Loss of long-duration response to levodopa over time in PD: implications for wearing-off

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Motor response to apomorphine and levodopa in asymmetric Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Influence of meal ingestion time on pharmacokinetics of orally administered levodopa in parkinsonian patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Long-term duodenal infusion of levodopa for motor fluctuations in parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Duodenal delivery of levodopa for on-off fluctuations in parkinsonism: preliminary observations.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Ten years' experience with enteral levodopa infusions for motor fluctuations in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

The "on-off" phenomenon in Parkinson's disease. Relation to levodopa absorption and transport

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Inhibition of L-[18F]fluorodopa uptake into human brain by amino acids demonstrated by positron emission tomography

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Clinical Efficacy of a Single Afternoon Dose of Effervescent Levodopa-Carbidopa Preparation (CHF 1512) in Fluctuating Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Effects of L-dopa on extracellular dopamine in striatum of normal and 6-hydroxydopamine-treated rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Real-time decoding of dopamine concentration changes in the caudate?putamen during tonic and phasic firing

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Unilateral dopamine denervation blocks corticostriatal LTP

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Firing regulation in dopaminergic cells: effect of the partial degeneration of nigrostriatal system in surviving neurons

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Evidence of a breakdown of corticostriatal connections in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Responses of pallidal neurons to striatal stimulation in monkeys with MPTP-induced parkinsonism

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Abnormal influences of passive limb movement on the activity of globus pallidus neurons in parkinsonian monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Changes in the regional and compartmental distribution of FosB- and JunB-like immunoreactivity induced in the dopamine-denervated rat striatum by acute or chronic L-dopa treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Continuous and intermittent levodopa differentially affect basal ganglia function

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Continuous and intermittent levodopa differentially affect rotation induced by D-1 and D-2 dopamine agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Levodopa replacement therapy alters enzyme activities in striatum and neuropeptide content in striatal output regions of 6-hydroxydopamine lesioned rats

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Continuous dopamine-receptor stimulation in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Intermittent vs Continuous Levodopa Administration in Patients With Advanced Parkinson Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

COMT inhibitors in Parkinson's disease: can they prevent and/or reverse levodopa-induced motor complications?

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1353-8020%2809%2970005-7

7 January 2021

10.1016/S1353-8020(09)70005-7

Identifiers

DOI

1 reference

19 August 2017

1 reference